PROCJENA KVALITETE ŽIVOTA U BOLESNIKA S ULCEROZNIM KOLITISOM by Gomez, Alvaro
  
UNIVERSITY OF SPLIT 
SCHOOL OF MEDICINE 
 
 
Alvaro Gomez Diaz 
 
ASSESMENT OF QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE 
COLITIS  
 
Diploma thesis 
 
 
 
 
Academic year: 
2017/2018 
 
 
 
Mentor: 
Assist. Prof. Joško Božić, MD, PhD 
 
 
Split, July 2018 
 
  
UNIVERSITY OF SPLIT 
SCHOOL OF MEDICINE 
 
 
Alvaro Gomez Diaz 
 
ASSESMENT OF QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE 
COLITIS  
 
Diploma thesis 
 
 
 
 
Academic year: 
2017/2018 
 
 
 
Mentor: 
Assist. Prof. Joško Božić, MD, PhD 
 
 
Split, July 2018 
  
  
TABLE OF CONTENTS 
 
1. INTRODUCTION ................................................................................................................. 2 
1.1. Definition ........................................................................................................................ 2 
1.2. Epidemiology .................................................................................................................. 2 
1.3. Pathophysiology .............................................................................................................. 3 
1.4. Risk factors ...................................................................................................................... 4 
1.5. Diagnosis ......................................................................................................................... 5 
1.6. Clinical presentation ........................................................................................................ 6 
1.7. Treatment ........................................................................................................................ 7 
1.9. Complications of UC ....................................................................................................... 8 
1.8. Quality of life in UC........................................................................................................ 9 
2. OBJECTIVES ...................................................................................................................... 11 
3. SUBJECTS AND METHODS ............................................................................................ 13 
3.1. Study design ...................................................................................................................... 14 
3.2. Ethical considerations ................................................................................................... 14 
3.3. Subjects ......................................................................................................................... 14 
3.4. HRQoL assessment ....................................................................................................... 14 
3.5. Statistical analysis ......................................................................................................... 15 
4. RESULTS ............................................................................................................................ 16 
5. DISCUSSION ...................................................................................................................... 22 
6. CONCLUSION .................................................................................................................... 25 
7. REFERENCES .................................................................................................................... 27 
8. SUMMARY ......................................................................................................................... 34 
9. CROATIAN SUMMARY ................................................................................................... 36 
10. CURRICULUM VITAE .................................................................................................... 38 
 
 
  
 
 
ACKNOWLEDGEMENT 
 
First and foremost, I would like to take this opportunity to express my sincere sense of 
gratitude and appreciation to my mentor, Assist. Prof. Joško Božić, MD, PhD. Without his 
guidance I would never be able to accomplish this thesis.  
 
This thesis would not have been possible without the enthusiastic support, the helpful 
comments and the remarkable patience of my thesis advisors, Josipa Bukić, MPharm and 
Doris Rušić, MPharm. I cannot thank them enough.  
 
I dedicate this humble work to my family, friends and to all the professors that shared their 
knowledge and inspired me to achieve my dream of becoming a doctor.
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. INTRODUCTION
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Inflammatory bowel disease (IBD) is a spectrum of chronic immune-mediated 
intestinal conditions which has slowly become a worldwide healthcare problem with 
increasing incidence. Ulcerative colitis (UC) and Crohn’s disease (CD) represent the two 
distinctive types of IBD. However, 4% of IBD cases cannot be defined as either CD or UC 
(1). 
The highest incidence rates and prevalence of UC and CD have been reported from 
northern Europe, the UK and North America. In low-incidence areas like southern Europe, 
Asia and other developing countries the incidence is rising (2). 
CD causes transmural inflammation and any part of the gastrointestinal tract can be 
affected. However, most commonly affected parts of gastrointestinal tract in patients with CD 
are terminal ileum or perianal region. The inflammation in CD is not necessarily confluent, 
frequently areas of relatively normal mucosa can be found. Furthermore, transmural nature of 
the inflammation in CD may lead to fibrosis and formation of strictures and fistulas. IBD is 
frequently accompanied with extra intestinal manifestations involving the joints, skin or eyes 
(1,3,4).  
IBD has been associated with many comorbidities such as psychiatric disorders, skin 
conditions and neurologic disorders. Anxiety disorder and depression are considerably more 
prevalent in IBD patients than in the general population (5). 
 
1.1. Definition 
UC is an idiopathic chronic disorder characterized by a mucosal inflammation of the 
colon. The disorder begins in the rectum and extents proximally in a continuous pattern. The 
portion of the colon affected can vary. Some individuals have inflammation that is limited to 
the rectum (ulcerative proctitis). In contrast, other patients have a more proximal disease. 
Pancolitis is the term referred to UC in which the entire colon is affected (6). Alternating 
periods of remission and relapse characterize UC. Furthermore, active forms of UC can range 
from mild to moderate or severe disease (7,8). 
 
1.2. Epidemiology  
The incidence of UC is higher than the incidence of CD. The highest incidence and 
prevalent rates of UC have been observed in North America and northern Europe. 
Furthermore, UC is characterized by having a bimodal pattern of incidence. The main peak of 
onset is in between 15 and 30 years of age, and the second smaller peak is in between 50 and 
70 years of age. The prevalence of UC is very similar between men and women, unlike CD, 
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which has a higher incidence in women. However, some studies have shown that UC has a 
slight predilection for men. In the US, the amount of patients with UC did not vary 
significantly by race. Smokers and patients who have had an appendectomy were less likely to 
develop the disease (2,7,9). 
Recently published article by Despalatović et al. investigated the epidemiological 
trends of IBD in Split-Dalmatia County from 2006 to 2014. During this period 414 
individuals older than 18 years were diagnosed with IBD. Moreover, 68.5% of these patients 
were diagnosed with UC, 47% of which were females (10).  
 
1.3. Pathophysiology  
The exact pathogenesis of UC remains mostly unknown. However, numerous studies 
concluded that in genetically predisposed individuals composition of intestinal flora, epithelial 
cell barrier function and immune responses interact to create a state of dysregulated mucosal 
immune function (1).  
Several studies have shown that microorganisms are likely to have a role in the 
development of UC. Animal studies have showed that colitis did not develop in sterile 
conditions but it was provoked after introduction of commensal bacteria. Moreover, it was 
detected that when stool was diverted from the active mucosal inflammation, like in an 
ileostomy, the inflammation was reduced (11).  
Some recent studies showed that UC is a disease product of a dysregulated innate 
immune system which activates T cells and a humoral response. Antigen presenting cells 
produce IL-23 which activates Th17 (11). Immunologic background of UC (and both CD) 
pathophysiology is presented in Figure 1.  
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Figure 1. Proposed pathogenesis of UC 
 
SOURCE: MacNaughton WK, Sharkey KA. Pharmacotherapy of Inflammatory Bowel 
Disease. In: Brunton LL, Hilal-Dandan R, Knollman BC, editors. The pharmacological basis 
of therapeutics. 13th ed. New York: McGraw-Hill; 2018. p. 945-54. 
 
 
1.4. Risk factors 
The etiology of IBD is still mostly unknown. However, it includes a complex 
interaction between environmental factors, genetics and immune responses.  
Most important independent risk factor is a family history of IBD (12). It has been 
shown that 5.7 - 15.5% of patients with UC have a first degree family member with the same 
condition. Additionally, studies conducted among Ashkenazi Jews showed that the rates of 
UC were 3 to 5 times higher than in other ethnicities. Finally, recent studies revealed that the 
environmental factors could influence genetically predisposed individuals (7). 
Several environmental factors have been recognized as either triggers or protective 
factors for UC. Among the investigated factors, only appendectomy and cigarette smoking 
had a well-known influence on the risk of developing UC. According to previously published 
data, cigarette smoking is protective against UC compared with the individuals that do not 
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smoke. Furthermore, smokers tend to have a milder disease course than patients who do not 
smoke. Moreover, it was observed that disease activity was increased in patients who ceased 
smoking (13,14).  
Several studies associated gastrointestinal infections (Salmonella, Campylobacter, 
Shigella etc.) to an increased risk of UC development (15,16). 
 
1.5. Diagnosis  
 Diagnosis of UC is based on the patient’s medical history and clinical symptoms. 
However, it should be confirmed by endoscopic, histologic, laboratory, radiologic and 
serological examinations (17,18).  
Clinical, endoscopic and pathological features of UC are presented in Table 1. 
According to previously published guidelines, before the diagnosis is made, other causes of 
diarrhea should be excluded.  
Most common other causes can be non infectious (e.g. tumors, microscopic colitis, 
drug induced diarrhea) and infectious diseases (1,17). CD may sometimes have a similar 
presentation to UC so some of the most commonly found features that can distinct UC and 
CD are: presence of perianal disease, absence of rectal inflammation and granulomas on 
endoscopy (19).  
Chronic diarrhea and bleeding can be induced by medications such as nonsteroidal 
anti-inflammatory drugs (NSAIDs), retinoic acid and mycophenolate (20). Infectious colitis 
can have similar endoscopic appearance and clinical presentation as UC. Patients who are 
presenting with this clinical manifestations should be excluded with stool culture, and 
biopsies of the colon (3).  
Inflammation usually starts in the rectum and extends proximally in a continuous 
pattern limited to a part of, or to the entire colon. However, some individuals with left-sided 
colitis or proctitis have rectal sparing and cecal patch of inflammation. The extent of the 
mucosal inflammation should be assessed at diagnosis in order to select an appropriate 
treatment (1,11,19).  
Apart from disease diagnosis, endoscopy in IBD plays a major role in prediction of 
disease severity and extent (i.e. mucosal healing) for tailored patient management and for 
screening of colitis-associated cancer and its precursor lesions. Classification is based on the 
number of stools per day and systemic symptoms of inflammation, such as tachycardia and 
fever (12,19,21).  
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Table 1. Diagnosis of ulcerative colitis 
Clinical features Endoscopic features Pathological features 
Rectal bleeding Loss of vascular pattern Distortion of crypt architecture 
Diarrhea Erythema Crypt abcesses 
Urgency Granularity 
Lamina propria cellular 
infiltrate 
Tenesmus Friability Shortening of the crypts 
Abdominal pain Erosions Mucin depletion 
Fever (severe cases) Ulcerations Lymphoid aggregates 
Extra intestinal 
manifestation 
Spontaneous bleeding Erosion or ulceration 
SOURCE: Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. 
Lancet. 2012;380(9853):1606-19.  
 
1.6. Clinical presentation 
In patients with UC clinical symptoms usually develop over time, rather than 
suddenly. UC can be debilitating and sometimes it can lead to life-threatening complications. 
Depending on the severity of the inflammation and where it occurs signs and symptoms may 
vary. The main symptoms include: bloody diarrhea (sometimes containing pus), abdominal 
pain, cramps, urgency to defecate, tenesmus, rectal bleeding, weight loss, fatigue and fever 
(1).  
In children diagnosed with UC limited has often been observed. Most people with UC 
have mild to moderate manifestations. The course of UC may vary, with some patients having 
long periods of remission (22,23). 
UC is classified according to the extent of the involvement. This classification 
includes: proctitis (when the disease is confined to the rectum), proctosigmoiditis, left sided 
colitis (affecting descending colon up to the splenic flexure) and pancolitis (extending from 
the rectum to the caecum) (24). 
The disease course can be affected with several factors. For instance, patients with late 
onset UC (diagnose at age 50 years or older) were more likely to achieve clinical remission 
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without the need for use of corticosteroids, in comparison with patients that had early onset 
UC (diagnosed between ages 18 and 30 years) (25).  
Furthermore, another important factor is the appendectomy. Patients who underwent 
appendix removal at a younger age, and before they were diagnosed with UC, had lower risk 
of hospitalizations and need for colectomy, in comparison with the patients who did not have 
appendectomy surgery (26). 
Patients with UC may present with extra intestinal manifestations. Several studies 
reported that the frequency of these complications (outside the colon) is somewhere between 
6 and 47% and they include: aphtous ulcers in the mouth, iritis, uveitis, episcleritis, 
seronegative arthritis, ankylosing spondilitis, sacroilitis, erythema nodosum (an inflammation 
of the subcutaneous tissue involving lower extremities), pyoderma gangrenosum (painful 
ulceration of the skin), deep venous thrombosis, autoimmune hemolitic anemia, clubbing 
fingers and primary sclerosing cholangitis (27). 
The most frequently reported extra intestinal manifestation among UC patients has 
been arthritis. Peripheral arthritis and ankylosing spondylitis are the most common types 
observed in UC patients. Previous studies associated UC patients that use corticosteroids with 
lower bone mineral density and higher risks of osteoporosis and fragility fractures (3,28).  
Patients that complain about burning, redness or itching sensation of the eyes should 
be referred to an ophthalmologist due to possible extra intestinal manifestations of UC such as 
uveitis and episcleritis (29).  
 
1.7. Treatment 
Therapeutic agents of UC include aminosalicylates, corticosteroids, thiopurines, 
cyclosporine and biological agents. In spite of many pharmacological approaches, there is still 
a need for implementation of newer therapies, because the existing therapies achieve low 
remission rate or unbearable side effects (30) . 
 However, recently published systematic review by Kokkindis et al. concluded that 
novel biological therapies as vedolizumab and gomumab showed promising efficacy and had 
satisfactory adverse effects profile. Further studies are needed to confirm the findings 
presented in this study (31).  
According to Clinical practice guidelines published in 2015, 5-aminosalicylic acid (5-
ASA) has been recognized as the first line therapy for mild to moderate UC. In patients with 
active proctitis, 5-ASA for rectal application has been recommended. Enemas are 
recommended in patients with active left sided UC, and oral form is recommended to patients 
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in whom disease has extended beyond proctitis. Clinicians are advised to evaluate lack of 
response to 5-ASA in 4 to 8 weeks in order to determine if there is a need for therapy 
modification. If 5-ASA does not induce remission, patients should use corticosteroids (8). 
Furthermore, adverse effects with 5-ASA are rare, and all patients with UC who tolerate this 
drug, should use 5-ASA (32). 
Corticosteroids should be advised to patients who failed to achieve remission with 
other medication. However, long term use of corticosteroids is not safe and should not be used 
to maintain the remission (30). If the steroid resistance in UC occurs, aminosalicylates, the 
immunomodulators (azathioprine, 6-mercaptopurine or methotrexate), adalimumab, 
infliximab or calcineurin inhibitors such as cyclosporine or tacrolimus can be administered 
(33). 
Medical therapy cannot always achieve an improvement in patients with severe acute 
or chronic colitis. For those patients surgical intervention is the next step. The most common 
surgical approach in the setting of acute and fulminant UC is total colectomy with a Hartman 
pouch. Posteriorly this can be converted into a total proctocolectomy with end -ileostomy or 
an ileal pouchanal anastomosis. Majority of the patients prefer the ileal poucheanal 
anastomisis because it keeps the flow of stool through the anus avoiding a permanent ostomy 
(34,35,36). 
Perforation, toxic megacolon or carcinoma are absolute indications for surgical 
intervention in patients with UC. Hartman’s pouch is well tolerated by majority of the patients 
who undergo surgery. However, 50% of the patients will develop pouchitis, and about 10 to 
12% will develop chronic pouchitis (37,38). 
Usually the patients with an ileal poucheanal anastomosis will experience 4 to 6 bowel 
movements a day but this can be efficiently reduced by the use of loperamide and fiber 
supplements (37,38). 
A literature review performed recently showed that the patients quality of life 1 year 
after surgery was equivalent to that in the general population. Even though there are potential 
benefits of surgery, colectomy is associated with a 54% of reoperation due to postsurgical 
complications (39,40). 
 
1.9. Complications of UC 
 Acute complications of UC include lesions, severe bleeding, fulminant colitis, toxic 
megacolon and perforation. Bleeding can occur in any stage of the UC, and it has usually 
been reported in up to 3% of patients. Urgent colectomy is necessary treatment in patients 
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with massive hemorrhage. However, lesions in UC patients can occur even after colectomy 
(41).  
Fulminant colitis can lead to the development of toxic megacolon. Toxic megacolon 
represents a life threatening complication of mostly infectious or inflammatory conditions of 
the colon. Recently, the epidemiology has shifted toward infectious origins, particulary due to 
an increase of Clostridium difficile-associated colitis associated with extensive use of 
antibiotics (42,43).  
Furthermore, toxic megacolon is usually associated with colonic diameter around 6 cm 
or cecal diameter around 9 cm and systemic toxicity. Untreated toxic megacolon can often 
lead to perforation and increased mortality of patients with UC (44). 
 Cronic complications of UC include strictures and development of colorectal cancer. 
Frequent episodes of inflammation and muscle hypertrophy are the main causes of the benign 
strictures in patients with UC. Strictures can most often occur in the rectosigmoid segment of 
the colon and in some cases it can lead to the obstruction of the lumen (45).  
Additionally, strictures should be evaluated by endoscope with a biopsy, to exclude 
the possible malignancy of the strictures. If the strictures cannot be completely evaluated for 
exclusion of malignancy, and if the patients report recurrent obstruction symptoms, surgical 
intervention should be strongly considered (46). 
Patients with UC have higher risk for developing colorectal cancer. Numerous studies 
confirmed this association. Colorectal cancer has been recognized as one of the most serious 
consequences of UC. Previous studies have shown that incidence of colorectal cancer is 
higher in UC patients who were younger at the time they were diagnosed, had greater 
anatomical extent of the disease and family history of colorectal cancer. In order to reduce the 
risk of colorectal cancer, and mortality of patients, patients are recommended to obtain regular 
colonoscopy examinations. Several studies have concluded that 5-aminosalicylates might 
prevent colorectal cancer and should be first line therapy in high risk patients (21,47,48). 
 
1.8. Quality of life in UC 
In some recent studies it was shown that adaptation to UC is very complex and that 
pharmacotherapy alone is most often insufficient to regain and maintain a “normal life”. 
Individuals with UC suffer from recurrent clinical signs and symptoms, like rectal bleeding, 
anemia, profuse diarrhea, fecal urgency and abdominal pain (49). 
Patients with IBD experience concerns that go beyond clinical symptoms of their 
disease; anxiety and depression due to a lack of control of their body functions, fear of disease 
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progression, hospitalization and surgery. They also report many limitations in the ability to 
enroll in social or recreational activities, school, work and subsequent difficulties for 
establishing relationships with others due to the constant urge to access the toilet (50,51). 
Previously published survey reported that following colectomy, UC individuals have a 
quality of life equivalent with that of the general population (52,53). However, patients should 
accept the potential risks of a challenging surgical intervention to remove the colon, its 
postoperative complications, infertility, lifelong stomy and pouchitis. Moreover, this 
procedure may heal individuals with colonic disease but it does not completely eliminate 
symptoms of incontinence and fecal urgency (53,54). 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
2. OBJECTIVES
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OBJECTIVES: 
1. Determine the differences in quality of life between UC patients and control group 
2. Determine the differences in quality of life between patients with active and not active UC 
 
HYPOTHESIS: 
1. Patients with UC will have reduced quality of life when compared to control group 
2. Patients with active disease will report reduced quality of life compared to patients who are 
in remission 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. SUBJECTS AND METHODS 
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3.1. Study design 
 This cross-sectional, questionnaire-based study was conducted at Department of 
Gastroenterology and Hepatology (University Hospital of Split) and Department of 
Pathophysiology (University of Split School of Medicine). Study was performed from 
December 2017 to May 2018. All participants were informed about procedures, course and 
aim of this study.  
 
3.2. Ethical considerations 
 Written informed consent was obtained from all individual participants included in the 
study. The study protocol was approved by the Ethics Committee of the University of Split 
School of Medicine and University Hospital of Split. All procedures performed in studies 
involving human participants were in accordance with the ethical standards of the institutional 
and/or national research committee and with the 1964 Helsinki declaration and its later 
amendments or comparable ethical standards. 
 
3.3. Subjects 
 This study included 30 patients with ulcerative colitis and 30 age and sex matched 
control subjects. The diagnosis is based on the history, as well as clinical, radiological, 
endoscopic and histological features in accordance with European Crohn's and Colitis 
Organisation (ECCO) consensus on the diagnosis and management of ulcerative colitis (55). 
Remission is defined as complete resolution of symptoms self-reported from the patient. 
Information about disease duration was taken from patients’ medical documentation.   
 Subjects included in the study underwent a detailed medical history interview, physical 
examination, and anthropometric measurements. Body height and weight were measured 
followed by the calculation of body mass index (BMI).  
  
3.4. HRQoL assessment 
 Health-related quality of life (HRQoL) was measured by Medical Outcomes Study Short 
Form-36 (SF-36) questionnaire which has been well established instrument for HRQoL 
assessment. SF-36 is a multifunctional, non-disease specific, 36-item health survey that 
evaluates 8 domains of health providing an overall assessment of HRQoL (56). 
Health aspects that are being valued are physical functioning (10 items), role 
limitations due to physical health (4 items), role limitations due to emotional health (3 items), 
energy/fatigue (4 items), emotional well-being (5 items), social functioning (2 items), bodily 
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pain (2 items) and general health perception (5 items). Each item is scored on a 0 to 100 scale 
so that the lowest and highest possible scores are 0 and 100, respectively. Furthermore, items 
in the same scale are averaged together to create the 8 scale scores, where higher score 
indicates better HRQoL (57). 
 
3.5. Statistical analysis 
 Statistical software MedCalc ver. 11.5.1.0 for Windows (MedCalc Software, Ostend, 
Belgium) was used for statistical data analysis. Data were expressed as means ± standard 
deviation for continuous variables and as whole numbers and percentage for categorical 
variables. Kolmogorov-Smirnov test has been used for normality of data distribution. Student 
t-test was used for comparison of different domains of SF-36 between UC and control group. 
Pearson’s correlation coefficient was used for assessment of correlation between SF-36 
variables and other variables. The statistical significance was defined as P<0.05.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. RESULTS
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 Table 2 describes the baseline parameters which were measured in patients with UC and 
in control group. Both groups consisted of participants of both genders with no significant 
difference in anthropometric parameters between the groups. Less smoker individuals were 
observed in UC group in comparison to the control group. However, this finding was not 
considered statistically significant. 
 
Table 2. Subjects’ characteristics 
SF-36 domain 
UC group 
(N=30) 
Control group 
(N=30) 
P* 
Age (years) 40.4±14.0 38.6±11.3 0.585 
Gender    
Men (N) 18 (60%) 15 (50%) 
0.440† 
Women (N) 12 (40%) 15 (50%) 
Body weight (kg) 78.9±17.4 83.1±16.6 0.340 
Body height (cm) 177.6±8.5 178.3±10.0 0.782 
BMI (kgm
-2
) 24.8±4.0 26.0±3.4 0.250 
Smokers (N) 2 (6.7%) 7 (23.3%) 0.145‡ 
Data is presented as mean±standard deviation or number (percentage) where appropriate 
*students’ t-test for independent samples 
†chi-square test 
‡ Fischer’s exact test 
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Distribution of patients relative to the duration of the disease given in years is 
presented in Figure 2. Most of the patients were diagnosed with ulcerative colitis up to 10 
years prior to the study. 
 
 
Figure 2. Distribution of patients relative to the duration  
of the disease in years 
 
 
 The results of SF-36 questionnaire are presented in Table 3. Interestingly, the only 
significant differences between groups were observed in 2 domains, domain role limitations 
due to physical health and domain general health. However, mean values in UC group for all 
8 domains were considerably lower than the mean values in control group. 
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Table 3. SF-36 domains  
SF-36 domain 
UC group 
(N=30) 
Control group 
(N=30) 
P* 
Physical functioning 81.7±21.0 88.8±16.1 0.144 
Role limitations due to physical health 70.8±41.6 94.2±11.2 0.004 
Role limitations due to emotional 
problems 
80.0±32.3 86.7±20.7 0.345 
Energy/fatigue 58.0±17.5 65.0±16.7 0.118 
Emotional well-being (mental health) 68.0±13.2 73.3±12.2 0.108 
Social functioning 77.9±21.2 85.4±15.8 0.125 
Pain 77.6±18.3 85.3±16.3 0.092 
General health 52.7±19.6 72.3±16.8 <0.001 
Data is presented as mean±standard deviation 
*students’ t-test for independent samples 
 
 Self-assessment of quality of life is presented in Figure 3. Patients with ulcerative colitis 
perceived their quality of life as significantly lower than control patients. 
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*students’ t-test for independent samples 
Figure 3. Self-assessment of quality of life in patients with  
ulcerative colitis (UC) (N=30) compared to healthy controls (N=30) 
 
Table 4. Ulcerative colitis duration correlation to SF-36 domains 
SF-36 domain r P* 
Physical functioning -0.519 0.003 
Role limitations due to physical health -0.434 0.017 
Role limitations due to emotional problems -0.104 0.585 
Energy/fatigue -0.051 0.789 
Emotional well-being (mental health) -0.195 0.303 
Social functioning -0.182 0.337 
Pain -0.334 0.071 
General health -0.358 0.050 
* Pearson correlation test 
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Statistically significant negative correlation was found between UC duration and 3 
domains of SF-36 questionnaire: physical functioning (r=-0.519, P=0.003), role limitations 
due to physical health (r=-0.434, P=0.017) and general health (r=-0.358, P=0.050) (Table 4). 
There was no significant correlation observed between disease duration and other domains of 
the SF-36 questionnaire. 
Quality of life, as measured with SF-36 questionnaire, remains similar among patients 
regardless of their disease activity. There were no significant differences observed in any SF-
36 domain, among patients with active UC and patients whose disease is currently not active 
(Table 5). 
 
Table 5. SF-36 domains with reference to disease activity 
SF-36 domain 
UC active 
(N=18) 
UC not active 
(N=12) 
P* 
Physical functioning 90.0 (80.0-100.0) 80.0 (72.5-100.0) 0.519 
Role limitations due to physical 
health 
100.0 (25.0-100.0) 100.0 (37.5-100.0) 0.962 
Role limitations due to 
emotional problems 
100.0 (66.7-100.0) 100.0 (66.6-100.0) 0.659 
Energy/fatigue 55.0 (45.0-65.0) 55.0 (47.5-70.0) 0.848 
Emotional well-being (mental 
health) 
66.0 (60.0-76.0) 66.0 (60.0-72.0) 0.610 
Social functioning 75.0 (50.0-100.0) 87.5 (68.8-100.0) 0.561 
Pain 80.0 (67.5-90.0) 77.5 (61.3-90.0) 0.482 
General health 57.5 (45.0-75.0) 42.5 (30.0-60.0) 0.168 
Data is presented as median (interquartile range) 
*Mann-Whitney test 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. DISCUSSION 
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UC is a disease affecting millions of patients worldwide with a significant impact on 
their quality of life (58). Furthermore, with the introduction of novel biological treatments, 
management of UC is costly for health care systems (59). The present study was made in 
order to confirm the recent investigations concerning this health issue by comparing quality of 
life of patients with UC and healthy controls at the Department of Gastroenterology and 
Hepatology, University Hospital of Split. 
 In the present study differences were observed in results of SF-36 questionnaire domains 
analysis between patients with UC and control group. UC patients scored lower in all domains 
of SF-36 questionnaire which translates to lower quality of life in patients with UC. This 
finding was observed in previous studies (60,61,62). However, not all of the differences 
between groups were considered significant. The largest differences were observed in 
domains general health and role limitations due to physical health. The first domain consists 
of the questions that examine if patients are satisfied with their health in general and how they 
perceive their health in comparison with other people. Furthermore, upon self-assessment, 
patients with UC considered their quality of life to be significantly lower than controls. 
 Results of the present study suggest that patients with UC considered their health 
considerably inferior in comparison with the general health of people who are not suffering 
from the UC. Similar findings were observed in previously published studies (63,64). 
Interestingly, significant difference was found in domain Role limitations due to physical 
health, but not in domains Role limitations due to emotional problems, Emotional well-being 
or Social functioning. Previous studies have identified fecal incontinence and perianal disease 
as quality of life determining factors for patients with IBD (65). This study included more 
patients with active disease, than patients in remission, however patients reported no 
significant influence on the disease on their social or emotional well-being compared to 
controls.  
 One study conducted in Norway that included patients with similar anthropologic 
characteristics showed similar outcomes. Moreover, lower scores in SF-36 questionnaire of 
UC patients were observed only in the general health domain, in comparison to the general 
population (66).  
 The second domain, role limitations due to physical health, consists of the questions that 
examine if patients were limited in the amount of time spent on activities or if they were 
limited in kind of activities. Our results propose that UC has the capacity to restrict patients, 
and make them unable to accomplish their daily activities. Interestingly, none statistically 
significant differences were observed in other domains.  
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 However, study from Hjortswang et al. conducted on 300 patients with UC obtained the 
opposite results than the ones observed in the present study. The researchers concluded that 
patients’ health related quality of life was primarily impaired in the psychological and social 
domains and to a much lesser extent in physical domains (67). 
 The present study has showed that there is a negative correlation in between the duration 
of UC and SF-36 domains. This finding propose that patients who suffered from the disease 
for a longer period had a considerably lower self-perceived quality of life. However, this 
correlation was statistically significant in only 3 domains. The most significant finding was 
observed in the domain of physical functioning. The patients who were suffering from the 
disease for a longer period of time perceived more difficulties in accomplishing vigorous or 
moderate activities, lifting, climbing stairs, bending, walking and bathing or dressing 
themselves. This finding is subject to bias, as inevitably patients with longer duration of 
disease tend to be older in general. 
 The results of the present study did not show any difference between patients with active 
UC and patients with not active UC. However, this finding was unexpected since there is an 
increasing evidence that patients with active disease have significantly lower scores for all 8 
domains of SF-36 compared to patients who achieved a remission (63,64,68,69).  
 However, study from McMullan et al. described how particular patients with severe UC 
were capable to maintain a “sense of normality in life” probably due to the ability to adapt to 
their newly established condition and presence of social support (70). Furthermore, a study 
conducted among pediatric patients with IBD demonstrated that parents and medical staff 
tend to underestimate the quality of life of children with IBD (71). It is possible that both 
medical staff and general population tend to underestimate the quality of life in adult patients 
with IBD. 
 Previously conducted studies reported that in patients with IBD health literacy and 
education were significantly associated with self-perceived quality of life and health status 
(72). This study did not collect education data and did not asses health literacy in patients 
therefore the obtained results might be limited. However, due to the fact that in the present 
study significant difference was found only in domains role limitations due to physical health 
and general health we do not believe that patients included in this study were likely to 
underestimate their quality of life. However, a greater sample size might yield more accurate 
results that could be comparable to the results of previous studies. A greater sample size is 
needed to assess the differences in quality of life of patients with active UC and those with not 
active UC. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. CONCLUSION
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1. Patients with UC had a lower score in all SF-36 domains compared to the control group 
with statistical significance in domains of role limitations due to physical health and general 
health 
2. Statistically significant correlations between duration of the disease and SF-36 
questionnaire were observed in domains of physical functioning, role limitations due to 
physical health and general health 
3. There was no significant difference in patients’ self-perceived quality of life according to 
activity of the disease 
4. Patients with UC had significantly lower self-perceived quality of life compared with 
control group 
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8. SUMMARY
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Objectives: Adaptation to ulcerative colitis (UC) is very complex as it has a huge impact in 
the quality of life of those who suffer with it. In the present study the objective was to 
determine the differences in quality of life between UC patients and a control group. 
 
Patients and Methods: This study included 30 patients with ulcerative colitis and 30 age and 
sex-matched control subjects. The diagnosis was based on medical history in addition to 
clinical, radiological, endoscopic and histological features. Health-related quality of life 
(HRQoL) was measured by the Short Form-36 (SF-36) questionnaire, a multifunctional, non-
disease specific, 36-item health survey. Statistical software MedCalc ver. 11.5.1.0 for 
Windows (MedCalc Software, Ostend, Belgium) was used for statistical data analysis. 
 
Results: Significant differences between groups were observed in 2 domains, domain role 
limitations due to physical health and domain general health.  The mean value for the self-
assessment of quality of life for UC patients was 7 in comparison to the control group which 
had a mean value of 9. This demonstrated that patients with ulcerative colitis perceived their 
quality of life as significantly lower than the control patients. Negative correlation was found 
between UC duration and 3 domains of SF-36 questionnaire: physical functioning (r=-0.519, 
P=0.003), role limitations due to physical health (r=-0.434, P=0.017) and general health (r=-
0.358, P=0.050). There was no significant correlation observed between disease duration and 
other domains of the SF-36 questionnaire. Quality of life remains similar among patients 
regardless of their disease activity. There were no significant differences observed in any SF-
36 domains among patients with active UC and patients whose disease is currently not active. 
 
Conclusion: Results confirmed the hypothesis that patients with UC have reduced quality of 
life when compared to healthy individuals.  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9. CROATIAN SUMMARY
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Naslov: PROCJENA KVALITETE ŽIVOTA U BOLESNIKA S ULCEROZNIM 
KOLITISOM 
Ciljevi: Prilagodba ulceroznom kolitisu (UC) je vrlo složena jer ima veliki utjecaj na kvalitetu 
života onih koji pate od ove bolesti. U ovome radu cilj je bio utvrditi razlike u kvaliteti života 
između bolesnika s UC i kontrolne skupine. 
Pacijenti i metode: Ova studija obuhvatila je 30 bolesnika s ulceroznim kolitisom i 30 
kontrolnih ispitanika, slične dobi i spola. Dijagnoza se temeljila na medicinskoj povijesti uz 
kliničke, radiološke, endoskopske i histološke značajke. Kvaliteta života povezana sa 
zdravljem (HRQoL) mjerena je upitnikom SF-36, višenamjenskom, zdravstvenom anketom. 
Statistički softver MedCalc ver. 11.5.1.0 za Windows (MedCalc Software, Ostend, Belgija) 
korišten je za statističku analizu podataka. 
Rezultati: Značajne razlike među skupinama zabilježene su u 2 domene, domena ograničenja 
uloga zbog fizičkog zdravlja i domena općeg zdravstvenog stanja. Srednja vrijednost za 
samoprocjenu kvalitete života za pacijente s UC bila je 7 u usporedbi s kontrolnom skupinom 
koja je imala srednju vrijednost 9. To je pokazalo da su pacijenti s ulceroznim kolitisom znali 
da je njihova kvaliteta života znatno niža od kontrole pacijenata. Negativna korelacija je 
utvrđena između trajanja UC i 3 domene SF-36 upitnika: fizičko funkcioniranje (r = -0.519, P 
= 0.003), ograničenja uloga zbog tjelesnog zdravlja (r = -0.434, P = 0.017) i opće zdravstveno 
stanje (r = -0,358, P = 0,050). Nije zabilježena značajna korelacija između trajanja bolesti i 
ostalih područja SF-36 upitnika. Kvaliteta života ostaje slična među pacijentima bez obzira na 
njihovu aktivnost bolesti. Nije bilo značajnih razlika u bilo kojoj SF-36 domeni među 
pacijentima s aktivnim UC i bolesnicima čija je bolest trenutno neaktivna. 
Zaključak: Rezultati potvrđuju hipotezu da pacijenti s UC imaju smanjenu kvalitetu života u 
usporedbi sa zdravim pojedincima. 
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